{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:27:23Z","timestamp":1793212043214,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In women with inflammatory bowel disease, at least 3 months of preconception corticosteroid-free remission (CFREM) is recommended by experts in current consensus statements. However, data are lacking on the appropriate preconception remission period. We investigated the appropriate preconception CFREM period in women with ulcerative colitis to reduce maternal disease activity and adverse pregnancy outcomes (ie, preterm birth, low birth weight, and small for gestational age).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively examined 141 pregnancies in women with ulcerative colitis at 2 institutions. We categorized the patients into 3 subgroups by their preconception CFREM period (\u22653 months, &amp;gt;0 to &amp;lt;3 months, and non-CFREM). We also investigated disease activity during pregnancy and postpartum and adverse pregnancy outcomes in each group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During pregnancy, the rate of active disease was significantly lower in the \u22653 months and &amp;gt;0 to &amp;lt;3 months CFREM groups compared with that in the non-CFREM group (P &amp;lt; .001 and P = .0257, respectively). Postpartum, the rate of active disease was significantly lower in the \u22653 months CFREM group compared with that in the non-CFREM group (P = .0087). The preconception CFREM period of \u22653 months was an independent inhibitory factor for active disease during pregnancy and postpartum (adjusted odds ratio, 0.15; P = .0035; and adjusted odds ratio, 0.33; P = .027, respectively). Adverse pregnancy outcomes were less common in the &amp;gt;3 months CFREM group compared with those in the other groups, but this difference was not significant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A preconception CFREM period of more than 3 months may be appropriate for better maternal and adverse pregnancy outcomes, as recommended in consensus statements.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izac270","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T11:46:26Z","timestamp":1673696786000},"page":"726-734","source":"Crossref","is-referenced-by-count":5,"title":["Appropriate Preconception Corticosteroid-Free Remission Period in Pregnant Women With Ulcerative Colitis"],"prefix":"10.1093","volume":"30","author":[{"given":"Aya","family":"Ikeda","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Center, Yokohama City University Medical Center , Yokohama , Japan"},{"name":"Department of Gastroenterology, Yokohama City University Graduate School of Medicine , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3083-9600","authenticated-orcid":false,"given":"Reiko","family":"Kunisaki","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Yokohama City University Medical Center , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Aoki","sequence":"additional","affiliation":[{"name":"Perinatal Center for Maternity and Neonates, Yokohama City University Medical Center , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuki","family":"Yaguchi","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Yokohama City University Medical Center , Yokohama , Japan"},{"name":"Department of Gastroenterology, Yokohama City University Graduate School of Medicine , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Madarame","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Yokohama City University Medical Center , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Nishio","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Yokohama City University Medical Center , Yokohama , Japan"},{"name":"Department of Gastroenterology, Yokohama City University Graduate School of Medicine , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Ogashiwa","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Yokohama City University Medical Center , Yokohama , Japan"},{"name":"Department of Gastroenterology, Yokohama City University Graduate School of Medicine , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Nakamori","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Yokohama City University Medical Center , Yokohama , Japan"},{"name":"Department of Gastroenterology, Yokohama City University Graduate School of Medicine , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kimura","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Yokohama City University Medical Center , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Kannai-Suzuki Clinic , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Saigusa","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yokohama City University Graduate School of Medicine , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yokohama City University Graduate School of Medicine , Yokohama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"key":"2024050205522562300_CIT0001","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet."},{"key":"2024050205522562300_CIT0002","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2018","journal-title":"Lancet."},{"key":"2024050205522562300_CIT0003","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1053\/j.gastro.2018.06.043","article-title":"Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from Western countries","volume":"155","author":"Shah","year":"2018","journal-title":"Gastroenterology."},{"key":"2024050205522562300_CIT0004","first-page":"1091","article-title":"Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure","volume":"20","author":"Br\u00f6ms","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"2024050205522562300_CIT0005","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/MIB.0000000000001102","article-title":"The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease","volume":"23","author":"Kammerlander","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2024050205522562300_CIT0006","article-title":"European Crohn\u2019s and Colitis guidelines on sexuality, fertility, pregnancy, and lactation","author":"Torres","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024050205522562300_CIT0007","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/ecco-jcc\/jjaa225","article-title":"The influence of disease activity on pregnancy outcomes in women with inflammatory bowel disease: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024050205522562300_CIT0008","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/ibd\/izaa122","article-title":"The risk of adverse neonatal outcomes with maternal inflammatory bowel disease: a systematic review and meta-analysis","volume":"27","author":"Leung","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2024050205522562300_CIT0009","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.14309\/ajg.0000000000000186","article-title":"Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study","volume":"114","author":"Shitrit","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"2024050205522562300_CIT0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/apt.15539","article-title":"Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study","volume":"51","author":"Moens","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2024050205522562300_CIT0011","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/apt.16960","article-title":"Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer\u2019s global safety database","volume":"56","author":"Mahadevan","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"key":"2024050205522562300_CIT0012","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/apt.16192","article-title":"Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study","volume":"53","author":"Wils","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"2024050205522562300_CIT0013","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2024050205522562300_CIT0014","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.reprotox.2007.11.010","article-title":"Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis","volume":"25","author":"Rahimi","year":"2008","journal-title":"Reprod Toxicol."},{"key":"2024050205522562300_CIT0015","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.cgh.2017.02.041","article-title":"Use of thiopurines during conception and pregnancy is not associated with adverse pregnancy outcomes or health of infants at one year in a prospective study","volume":"15","author":"Kanis","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2024050205522562300_CIT0016","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/MIB.0000000000000092","article-title":"Anti-TNF alpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Narula","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"2024050205522562300_CIT0017","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","article-title":"Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development","volume":"155","author":"Matro","year":"2018","journal-title":"Gastroenterology."},{"key":"2024050205522562300_CIT0018","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-term safety of in utero exposure to anti-TNF\u03b1 drugs for the treatment of inflammatory bowel disease: results from the multicentre European TEDDY study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2024050205522562300_CIT0019","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/ibd\/izy294","article-title":"Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicentre observation","volume":"25","author":"Duricova","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"2024050205522562300_CIT0020","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology."},{"key":"2024050205522562300_CIT0021","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1136\/gutjnl-2021-325317","article-title":"Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry","volume":"71","author":"Odufalu","year":"2022","journal-title":"Gut."},{"key":"2024050205522562300_CIT0022","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology."},{"key":"2024050205522562300_CIT0023","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.cgh.2016.03.018","article-title":"Preconception care reduces relapses of inflammatory bowel disease during pregnancy","volume":"14","author":"de Lima","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2024050205522562300_CIT0024","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/ibd\/izz037","article-title":"Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group","volume":"25","author":"Mahadevan","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"2024050205522562300_CIT0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"Am J Med."},{"key":"2024050205522562300_CIT0026","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10620-020-06221-6","article-title":"Non-adherence to medications in pregnant ulcerative colitis patients contributes to disease flares and adverse pregnancy outcomes","volume":"66","author":"Watanabe","year":"2021","journal-title":"Dig Dis Sci."},{"key":"2024050205522562300_CIT0027","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/ibd\/izz250","article-title":"Early discontinuation of infliximab in pregnant women with inflammatory bowel disease","volume":"26","author":"Truta","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2024050205522562300_CIT0028","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/ibd.21522","article-title":"Self-reported adherence to medical treatment prior to and during pregnancy among women with ulcerative colitis","volume":"17","author":"Julsgaard","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"2024050205522562300_CIT0029","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","article-title":"Continuous anti-TNF\u03b1 use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National Health Insurance Database (EVASION)","volume":"113","author":"Luu","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2024050205522562300_CIT0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crohns.2007.11.001","article-title":"European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis","volume":"2","author":"Stange","year":"2008","journal-title":"J Crohns Colitis"},{"key":"2024050205522562300_CIT0031","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0022-3476(67)80066-0","article-title":"A practical classification of newborn infants by weight and gestational age","volume":"71","author":"Battaglia","year":"1967","journal-title":"J Pediatr."},{"key":"2024050205522562300_CIT0032","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/apt.12417","article-title":"Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease","volume":"38","author":"Abhyankar","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"2024050205522562300_CIT0033","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/ibd\/izab206","article-title":"Risk factors for postpartum disease activity in women with inflammatory bowel disease: a systematic review and meta-analysis","volume":"28","author":"Malhi","year":"2022","journal-title":"Inflamm Bowel Dis."},{"key":"2024050205522562300_CIT0034","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/ajg.2016.254","article-title":"The effects of active IBD during pregnancy in the era of novel IBD therapies","volume":"111","author":"de Lima-Karagiannis","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"2024050205522562300_CIT0035","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/apt.12412","article-title":"The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom study of 209 pregnant women","volume":"38","author":"Pedersen","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"2024050205522562300_CIT0036","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10620-020-06282-7","article-title":"Factors associated with inflammatory bowel disease flare during pregnancy among women with preconception remission","volume":"66","author":"Rottenstreich","year":"2021","journal-title":"Dig Dis Sci."},{"key":"2024050205522562300_CIT0037","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/ibd\/izz313","article-title":"Incidence and predictors of flares in the postpartum year among women with inflammatory bowel disease","volume":"26","author":"Yu","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2024050205522562300_CIT0038","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1572-0241.2005.40785.x","article-title":"The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease","volume":"100","author":"Kane","year":"2005","journal-title":"Am J Gastroenterol."},{"key":"2024050205522562300_CIT0039","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/ajg.2009.362","article-title":"A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period","volume":"104","author":"Moffatt","year":"2009","journal-title":"Am J Gastroenterol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izac270\/48713025\/izac270.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/5\/726\/57299550\/izac270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/5\/726\/57299550\/izac270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T05:54:26Z","timestamp":1714629266000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/5\/726\/6987566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,1,14]]},"published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izac270","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2023,1,14]]}}}